Original articleA Prospective Study of Reticular Macular Disease
Section snippets
Subjects
Data were used from the Nutritional AMD treatment phase II (NAT 2) Study, sponsored by Bausch & Lomb, Inc (Montpellier, France), which had a 3-year follow-up duration for each subject. The research adhered to the tenets of the Declaration of Helsinki and was approved by the Medical Ethics Committee of L'Hôpital Intercommunal de Créteil (Créteil, France). The NAT 2 Study was a prospective, single-center, double-blind, randomized, parallel, placebo-controlled, comparative study. The data set
Results
The 3-year NAT 2 Study yielded complete data for 271 subjects from a total of 300. The 29 subjects who did not complete the study were lost to follow-up, with 1 recorded death among them (an 86-year-old woman); these subjects were demographically similar to those who completed the full study (72.4%, or 21/29, female with an average age of 75±5.8 years). Among the subjects who completed the study, there was a significantly higher rate of progression to late-stage AMD in eyes with RPD at any
Discussion
Reticular macular disease, a subphenotype of AMD that includes RPD, has been shown to be associated with advanced AMD.3, 4, 5, 6, 7 This study, to the authors' knowledge, is the first prospective study that examines high-risk eyes with early AMD and demonstrates significantly increased progression to both types of advanced AMD (CNV and GA) among such subjects with RMD. It was found that 56% of eyes with RPD progressed to late-stage AMD: 45% of these progressed to CNV, 20% of these progressed to
References (21)
- et al.
The Wisconsin Age-Related Maculopathy Grading System
Ophthalmology
(1991) - et al.
Indocyanine green angiography of drusen
Am J Ophthalmol
(1997) - et al.
Prevalence and significance of subretinal drusenoid deposits (reticular pseudodrusen) in age-related macular degeneration
Ophthalmology
(2010) - et al.
An international classification and grading system for age-related maculopathy and age-related macular degeneration
Surv Opthhalmol
(1995) - et al.
Macular drusen [in French]
J Fr Ophtalmol
(1990) - et al.
Reticular pseudodrusen: a risk factor in age-related maculopathy
Retina
(1995) - et al.
Prevalence of reticular pseudodrusen in age-related macular degeneration with newly diagnosed choroidal neovascularization
Br J Ophthalmol
(2007) - et al.
Autofluorescence characteristics of early, atrophic, and high-risk fellow eyes in age-related macular degeneration
Invest Ophthalmol Vis Sci
(2006) - et al.
The epidemiology of retinal reticular drusen
Am J Ophthalmol
(2008) - et al.
Reticular macular disease
Am J Ophthalmol
(2009)
Cited by (134)
Subretinal drusenoid deposits, age-related macular degeneration, and cardiovascular disease
2024, Asia-Pacific Journal of OphthalmologyAge-related macular degeneration
2023, The LancetReticular Pseudodrusen on the Risk of Progression in Intermediate Age-Related Macular Degeneration
2022, American Journal of OphthalmologyCitation Excerpt :Our study is unable to comment on the prognostic significance of RPD in the fellow eye of individuals with late AMD in one eye. Several previous studies, including our own, have reported an association between RPD and an increased risk of developing late AMD14-19 or geographic atrophy (GA) only11,20 in the non-late, fellow AMD eyes of individuals with unilateral nAMD. Note, however, that in one of these studies, longer-term follow-up of individuals no longer revealed a significant association between RPD and an increased risk of disease progression.21
Reticular pseudodrusen: A critical phenotype in age-related macular degeneration
2022, Progress in Retinal and Eye ResearchThe role of dark adaptation in understanding early AMD
2022, Progress in Retinal and Eye Research
Manuscript no. 2010-1144.
Supported by grants from The New York Community Trust, New York, New York; the National Eye Institute, Bethesda, Maryland (grant no.: R01 EY015520 [RTS]); and unrestricted funds from Research to Prevent Blindness, Inc., New York, New York. The funding organizations had no role in the design or conduct of this research. Images from the NAT 2 Study were obtained from L'Hôpital Intercommunal de Créteil, Créteil, France, and Eric H. Souied, MD, PhD. ISRCTN (numeric system for the unique identification of randomized controlled trials) number for the NAT 2 Study: 98246501.
Financial Disclosure(s): The author (s) have made the following disclosure (s): Eric H. Souied - Consultant - Bausch & Lomb and Novartis; Lecturer - Alcon